US federal prosecutors in July claimed Ranbaxy's "violations have resulted and continue to result" in the importation of adulterated and misbranded medications. US regulators inspected Ranbaxy plants in India, Uganda and Nigeria and subpoenaed company records while the FBI raided the company's offices in Plainsboro, New Jersey, and a plant in New Brunswick, New Jersey.